How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,635 results for

Squamous Cell Carcinoma of the Skin

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

13841. Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer

metastases (or local treatment of brain metastases within the last 6 months) due to the poor prognosis of these patients and difficulty ascertaining the cause of neurologic toxicities. Pregnancy due to the possible adverse effects on the developing fetus. Lactating women who are breast-feeding due to the possibility of transmitting chemotherapy to the child. The presence of a second malignancy, other than squamous cell carcinoma of the skin or in situ cervical cancer because it will complicate (...) Neoplasms Adrenocortical Carcinoma Adrenal Gland Neoplasms Endocrine Gland Neoplasms Neoplasms by Site Neoplasms Adrenal Cortex Diseases Adrenal Gland Diseases Endocrine System Diseases Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Doxorubicin Liposomal doxorubicin Etoposide Etoposide phosphate Vincristine Mitotane Antibiotics, Antineoplastic Antineoplastic Agents Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms

2003 Clinical Trials

13842. S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

Negative pregnancy test Fertile patients must use effective contraception No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, in situ cervical carcinoma, or lobular carcinoma in situ of the breast Prior invasive breast cancer or ductal carcinoma in situ allowed if disease-free for 5 years HIV negative PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy No prior cytotoxic chemotherapy for this breast cancer No prior (...) remaining tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating resected breast cancer. PURPOSE: This randomized phase III trial is comparing 2 different regimens of combination chemotherapy to see how well they work in treating patients who have undergone surgery for stage I, stage II, or stage III breast cancer. Condition or disease Intervention/treatment Phase Breast Cancer Biological: pegfilgrastim Drug: AC regimen Drug: cyclophosphamide Drug

2003 Clinical Trials

13843. A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer

malignancies within 5 years of Day 1 except for adequately treated carcinoma in situ of the cervix, ductal carcinoma in situ of the breast, or basal or squamous cell skin cancer History of serious systemic disease, including active infection, uncontrolled hypertension (diastolic blood pressure >100 mmHg on two consecutive occasions), unstable angina, congestive heart failure, or myocardial infarction within 6 months prior to Day 1, or unstable symptomatic arrhythmia requiring medication (subjects (...) Identifier: Obsolete Identifiers: NCT00070408 Other Study ID Numbers: TOC2689g First Posted: April 9, 2003 Results First Posted: June 23, 2015 Last Update Posted: March 8, 2017 Last Verified: January 2017 Keywords provided by Genentech, Inc.: Advanced, refractory, or recurrent ovarian cancer Additional relevant MeSH terms: Layout table for MeSH terms Ovarian Neoplasms Carcinoma, Ovarian Epithelial Endocrine Gland Neoplasms Neoplasms by Site Neoplasms Ovarian Diseases Adnexal Diseases Genital Diseases

2003 Clinical Trials

13844. Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer

prior to Day 1, except for adequately treated basal or squamous cell skin cancer History of serious systemic disease, including active infection, uncontrolled hypertension (diastolic blood pressure >100 mmHg on two consecutive occasions), unstable angina, congestive heart failure, or myocardial infarction within 6 months prior to Day 1, or unstable symptomatic arrhythmia requiring medication (subjects with chronic atrial arrhythmia, i.e., atrial fibrillation, paroxysmal supraventricular tachycardia (...) : Genentech, Inc. Information provided by: Genentech, Inc. Study Details Study Description Go to Brief Summary: The purpose of this study is to evaluate safety and efficacy of Omnitarg (Pertuzumab) on cancerous lesions in men with castration-resistant (hormone-refractory) prostate cancer. Condition or disease Intervention/treatment Phase Prostate Cancer Drug: rhuMAb 2C4 (pertuzumab) Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment

2003 Clinical Trials

13845. Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer

with squamous or basal cell carcinoma of the skin, melanoma in situ, carcinoma in situ of the cervix, or carcinoma in situ of the colon or rectum that have been effectively treated are eligible, even if these conditions were diagnosed within 5 years prior to randomization. Exclusion Criteria: Findings of metastatic disease. On imaging, clear indication of involvement of the pelvic side wall(s). Rectal cancers other than adenocarcinoma, i.e., sarcoma, lymphoma, carcinoid, squamous cell carcinoma, cloacogenic (...) carcinoma, etc. History of invasive rectal malignancy, regardless of disease-free interval. Pregnancy or lactation at the time of proposed randomization. Eligible patients of reproductive potential (both sexes) must agree to use adequate contraceptive methods. Any therapy for this cancer prior to randomization. Synchronous colon cancer. History of viral hepatitis or other chronic liver disease. Nonmalignant systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude the patient from

2003 Clinical Trials

13846. S0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED)

of normal (ULN) Aspartate aminotransferase (SGOT) no greater than 2.5 times ULN If SGOT is greater than ULN, alkaline phosphatase must be no greater than 2.5 times ULN Alkaline phosphatase no greater than 4 times ULN If alkaline phosphatase is greater than ULN, SGOT must be no greater than 1.5 times ULN Renal Not specified Other Fertile patients must use effective contraception No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or stage I or II (...) : April 9, 2003 Last Update Posted : June 28, 2018 Sponsor: Southwest Oncology Group Collaborators: National Cancer Institute (NCI) Eastern Cooperative Oncology Group Information provided by (Responsible Party): Southwest Oncology Group Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy such as docetaxel use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of docetaxel in treating

2003 Clinical Trials

13847. Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer

patients must use effective contraception No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer Able to tolerate folic acid, corticosteroids, or cyanocobalamin supplements More than 4 weeks since prior biologic or immunologic therapy No prior biologic or immunologic therapy for metastatic disease No concurrent immunotherapy No concurrent colony-stimulating factors during course 1 No prior chemotherapy for metastatic disease No prior gemcitabine (...) by blocking the enzymes necessary for tumor cell growth. Combining gemcitabine with pemetrexed disodium may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of gemcitabine when given together with pemetrexed disodium to see how well it works in treating patients with unresectable or metastatic biliary tract or gallbladder cancer. Condition or disease Intervention/treatment Phase Extrahepatic Bile Duct Cancer Gallbladder Cancer Liver Cancer Drug: gemcitabine

2003 Clinical Trials

13848. Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a Taxane

are not considered acceptable forms of contraception No other invasive non-breast malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer No ongoing or active infection No psychiatric illness or social situation that would preclude study compliance No other concurrent uncontrolled illness PRIOR CONCURRENT THERAPY: Biologic therapy At least 2 weeks since prior immunotherapy No prior cetuximab Chemotherapy At least 2 weeks since prior chemotherapy and recovered No more (...) of tumor cells by blocking the enzymes necessary for tumor cell growth. Combining gemcitabine with erlotinib may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine with erlotinib in treating patients who have metastatic breast cancer that has been previously treated with an anthracycline and/or a taxane. Condition or disease Intervention/treatment Phase Breast Cancer Drug: erlotinib hydrochloride Drug: gemcitabine hydrochloride Phase 2 Detailed

2003 Clinical Trials

13849. Perifosine in Treating Patients With Recurrent Prostate Cancer

except for the following: adequately treated basal cell or squamous cell skin cancer, in situ carcinoma of any site, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided (...) Sponsor: National Cancer Institute (NCI) Information provided by (Responsible Party): National Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: Phase II trial to study the effectiveness of perifosine in treating patients who have recurrent prostate cancer. Drugs used in chemotherapy such as perifosine use different ways to stop tumor cells from dividing so they stop growing or die Condition or disease Intervention/treatment Phase Adenocarcinoma of the Prostate Recurrent

2003 Clinical Trials

13850. S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical Cancer

basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer currently in complete remission PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy More than 6 months since prior single-agent chemotherapy as a radiosensitizer Endocrine therapy Not specified Radiotherapy See Disease Characteristics At least 28 days since prior radiotherapy No prior radiotherapy to measurable target lesions No concurrent palliative radiotherapy (...) , 2003 Last Update Posted : June 13, 2012 Sponsor: Southwest Oncology Group Collaborator: National Cancer Institute (NCI) Information provided by (Responsible Party): Southwest Oncology Group Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether cisplatin is more effective when combined

2003 Clinical Trials

13851. Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer

an increased risk of ocular events; the decision to wear contact lenses should be discussed with the patient's treating oncologist and ophthalmologist Patients must not suffer from medical or psychiatric conditions that would interfere with protocol compliance, the ability to provide informed consent, or assessment of response or anticipated toxicities Patients must be disease-free of prior invasive malignancies for > 5 years with the exception of curatively-treated basal cell or squamous cell carcinoma (...) of breast cancer cells. Hormone therapy using anastrozole and fulvestrant may fight breast cancer by blocking the use of estrogen. Gefitinib (ZD1839) may stop the growth of cancer cells by blocking the enzymes necessary for their growth. It is not yet known whether gefitinib is more effective when combined with anastrozole or fulvestrant in treating breast cancer. Condition or disease Intervention/treatment Phase Estrogen Receptor-positive Breast Cancer Progesterone Receptor-positive Breast Cancer

2003 Clinical Trials

13852. Radiation Therapy With or Without Chemotherapy in Reducing Mouth Dryness in Patients With Nasopharyngeal Cancer

Hematopoietic White blood cell count (WBC) at least 4,000/mm^3 Platelet count at least 100,000/mm^3 Hepatic Not specified Renal Creatinine no greater than 1.6 mg/dL Creatinine clearance at least 60 mL/min Other Not pregnant (If stage T2b or greater or node-positive disease) Negative pregnancy test (If stage T2b or greater or node-positive disease) No other prior head and neck cancer No other malignancy within the past 5 years except nonmelanoma skin cancer No active untreated infection No other major (...) patients live more comfortably. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of specialized radiation therapy techniques with or without chemotherapy in reducing mouth dryness in patients who have nasopharyngeal cancer. Condition or disease Intervention/treatment Phase Head and Neck Cancer Oral Complications

2003 Clinical Trials

13853. Sildenafil in Treating Erectile Dysfunction in Patients With Prostate Cancer

Performance status Zubrod 0-2 Life expectancy Not specified Hematopoietic Not specified Hepatic Not specified Renal Not specified Cardiovascular No myocardial infarction within the past year Other No other invasive cancer within the past 5 years except localized basal cell or squamous cell skin cancer (stage 0-II) No anatomical genital abnormalities or concurrent conditions that would prohibit sexual intercourse or preclude study participation No other major medical or psychiatric illness that would (...) by Radiation Therapy Oncology Group: sexual dysfunction sexuality and reproductive issues radiation toxicity stage IIB prostate cancer stage IIA prostate cancer stage III prostate cancer psychosocial effects of cancer and its treatment Additional relevant MeSH terms: Layout table for MeSH terms Prostatic Neoplasms Erectile Dysfunction Radiation Injuries Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms Genital Diseases, Male Prostatic Diseases Sexual Dysfunction, Physiological Sexual

2003 Clinical Trials

13854. Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer

and for 3 months after study participation No active infection No pre-existing grade 2 or greater peripheral neuropathy No other concurrent medical condition that would preclude study participation No hypersensitivity to drugs formulated with Polysorbate 80 No other malignancy within the past 3 years except curatively treated squamous cell or basal cell skin cancer or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy: At least 2 weeks since prior biologic therapy Any number (...) recurrent squamous cell carcinoma of the larynx stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity recurrent salivary gland cancer salivary gland squamous cell carcinoma stage IV salivary gland cancer Additional relevant MeSH terms: Layout table for MeSH terms Head and Neck Neoplasms Neoplasms by Site Neoplasms Docetaxel Irinotecan Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators

2002 Clinical Trials

13855. BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

metastases, are not eligible Patients must have recovered from major infections and/or surgical procedures and, in the opinion of the investigator, not have significant active concurrent other medical illness precluding protocol treatment Men of reproductive potential must agree to use an effective contraceptive method No prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ carcinoma of any site, adequately treated stage I or II cancer (...) : National Cancer Institute (NCI) Information provided by (Responsible Party): National Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: BMS-275291 may stop the growth of prostate cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth. Randomized phase II trial to study the effectiveness of BMS-275291 in treating patients who have prostate cancer that has not responded to hormone therapy Condition or disease Intervention/treatment

2002 Clinical Trials

13856. Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer

heart failure No uncontrolled hypertension Other: No other malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or contralateral breast cancer No active unresolved infection No poorly controlled diabetes mellitus No prior hypersensitivity reactions to sulindac or Polysorbate 80 No peripheral neuropathy grade 2 or greater No active peptic ulcer disease Not pregnant or nursing Negative pregnancy test Fertile patients (...) : National Cancer Institute (NCI) Information provided by (Responsible Party): Fox Chase Cancer Center Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining sulindac with docetaxel in treating women who have metastatic or recurrent breast cancer. Condition or disease

2002 Clinical Trials

13857. Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer

Institute (NCI) Information provided by (Responsible Party): Gynecologic Oncology Group Study Details Study Description Go to Brief Summary: Phase II trial to study the effectiveness of capecitabine in treating patients who have persistent or recurrent cervical cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Condition or disease Intervention/treatment Phase Cervical Adenocarcinoma Cervical Adenosquamous Carcinoma Recurrent Cervical (...) below. For general information, Layout table for eligibility information Ages Eligible for Study: Child, Adult, Older Adult Sexes Eligible for Study: Female Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Histologically confirmed primary non-squamous cell carcinoma (non-SCC) of the cervix Persistent or recurrent disease Eligible subtypes include: Adenocarcinoma Adenosquamous cell carcinoma Undifferentiated carcinoma Documented disease progression At least 1 unidimensionally measurable

2002 Clinical Trials

13858. Comparison of Biomarkers Based on Fine-Needle Aspiration in Women at Increased or Normal Risk of Breast Cancer

and over Sex: Female Menopausal status: Not specified Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No active invasive malignancy in any site except basal cell or squamous cell skin cancer No significant medical or psychiatric problems that would preclude study No evidence of excessive use of narcotics or drug dependency PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified (...) carcinoma in situ lobular breast carcinoma in situ Additional relevant MeSH terms: Layout table for MeSH terms Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases

2002 Clinical Trials

13859. Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer

as long as both primary tumors; if a patient has an invasive cancer on one side that meets the eligibility criteria, and DCIS or LCIS on the contralateral side, the patient is eligible; DCIS or LCIS should be managed according to institutional guidelines Patients must be disease free from prior malignancies for > 5 years, except for curatively treated basal cell or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix; patients with a history of invasive breast cancer, or DCIS (...) (FISH) may receive trastuzumab There must be negative tumor margins for invasive cancer and ductal carcinoma in situ (DCIS) in the case of mastectomy or lumpectomy; lobular carcinoma in situ (LCIS) is acceptable at the margin Patients with multi-centric breast cancer are eligible as long as all known disease is resected with negative margins, and have 0-3 positive axillary lymph nodes Patients must be registered within 84 days of the last breast surgery; patients must have undergone either modified

2002 Clinical Trials

13860. Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer

Institute (NCI) Information provided by (Responsible Party): Gynecologic Oncology Group Study Details Study Description Go to Brief Summary: Phase II trial to study the effectiveness of docetaxel in treating patients who have persistent or recurrent cervical cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Condition or disease Intervention/treatment Phase Cervical Squamous Cell Carcinoma, Not Otherwise Specified Recurrent Cervical (...) antibiotics No greater than grade 1 sensory and motor neuropathy No other invasive malignancy within the past 5 years except nonmelanoma skin cancer At least 3 weeks since prior biologic or immunologic therapy directed at malignant tumor One prior noncytotoxic regimen (e.g., monoclonal antibodies, cytokines, or small-molecule signal transduction inhibitors) for recurrent or persistent disease allowed Recovered from prior chemotherapy No prior docetaxel No more than 1 prior cytotoxic chemotherapy regimen

2002 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>